|Articles|April 15, 2003
Cyclosporine emulsion offers severe dry eye relief
April 14-San Francisco-Cyclosporine ophthalmic emulsion 0.05% drops (Restasis,Allergan), approved 11 days ago, offers relief of dry eye symptoms by treatingthe inflammatory process that causes the condition, explained John D. Sheppard,MD, program and laboratory director, professor, departments of ophthalmologyand pharmacology, Eastern Virginia School of Medicine. He spoke during thesymposium, "Interdisciplinary Perspectives in Corneal Health Integrity,"sponsored by Allergan.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
2
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05%
3
Avisi Technologies treats first patient in SAPPHIRE trial for glaucoma
4
Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA
5











































.png)


